Article Sidebar
Published:
Nov 19, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of varied times of tirofiban administration on post-emergency percutaneous coronary intervention in patients with acute myocardial infarction
Abstract
Purpose: To determine the impact of time profile of tirofiban hydrochloride administration on short-term outcomes in patients with acute myocardial infarction (AMI) undergoing emergency percutaneous coronary intervention (PCI). Methods: A total of 112 patients with AMI who received PCI treatment in The First People's Hospital of Tianshui, Tianshui, China were randomly and equally assigned to study and control groups. The study group received intravenous tirofiban hydrochloride bolus (10 μg/kg) 1 - 2 h before PCI, followed by sustained infusion at 0.15 μg/kg/min for 36 h after the procedure. Control group received the same regimen immediately after PCI. Myocardial injury markers, cardiac functional parameters, ST-segment resolution, myocardial perfusion changes, bleeding complications, and adverse cardiovascular events over 6 months were evaluated. Results: When compared with control group, the study group exhibited significantly lower cardiac troponin T (cTnT) levels and lower serum creatine kinase-MB (CK-MB) levels at 7 days post-PCI (p < 0.05). Furthermore, the study group showed significantly reduced left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD), along with higher left ventricular ejection fraction (LVEF) after 7 days (p < 0.05). The study group also exhibited superior ST-segment resolution and significant improvement in myocardial perfusion 90 min post-treatment and significantly lower incidence of reperfusion arrhythmias (p < 0.05). Both groups had similar rates of minor bleeding events and no incidence of severe complications or fatalities. Conclusions: Administering tirofiban preoperatively enhances coronary blood flow, improves myocardial perfusion, and reduces the risk of distal embolic events without increasing severe bleeding complications. Larger-scale, multicenter studies with longer follow-up periods are required to confirm these findings and evaluate the safety and efficacy of different administration time for tirofiban infusion in patients with AMI undergoing PCI.
